Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial

Academic Article

Abstract

  • In this randomized pilot clinical trial, dolutegravir plus lamivudine was noninferior to continuation of standard 3-drug maintenance antiretroviral therapy. There was no emergence of drug resistance in the participant who experienced virologic failure while receiving dolutegravir plus lamivudine. Clinical Trials Registration NCT02263326
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Taiwo BO; Marconi VC; Berzins B; Moser CB; Nyaku AN; Fichtenbaum CJ; Benson CA; Wilkin T; Koletar SL; Colasanti J
  • Start Page

  • 1794
  • End Page

  • 1797
  • Volume

  • 66
  • Issue

  • 11